Takeda furthers innovation-focused strategy in china with sale of select non-core assets to hasten for $322 million usd

Osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core prescription pharmaceutical products sold in china to hasten biopharmaceutic co., ltd. (china) (“hasten”), a company funded by feidong county of hefei city, china and established by ray capital management limited (“ray capital”)1 takeda will receive $322 million usd, subject to customary legal and regulatory c
TAK Ratings Summary
TAK Quant Ranking